[Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin].

Lin HY

Zhonghua yi xue za zhi1 Feb 2007Cited by 23 (Europe PMC)

PMID17459221PepBankPUB-17459221

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In adults with severe sepsis, double-dose ulinastatin plus thymosin alpha1 lowered 28-day mortality compared with standard treatment.
In plain wordsIn adults with severe sepsis, ulinastatin plus thymosin alpha1 at double dose was linked to fewer deaths at 28 days than standard treatment.
Peptide
Thymosin alpha-1
Outcome
Decrease28-day mortality, second trial
Study
n = 342
Comparator
Standard treatment
Outcome group
Mortality · Infection
Measurements
28-day mortality
38.32%
control
28-day mortality
25.14%
treatment group 2
Source sentences
Summary
In the second trial (342 cases), the mortality of treatment group 2 decreased from 38.32% to 25.14% (P=0.0088), compared with group control at 28 days, and from 52.10% to 37.14% (P=0.0054) on 90 days.
2 context sentences(design, population, supporting numbers)
Summary · context
Totally, 433 adult patients developing severe sepsis with Marshall score 5-20 were enrolled.
Summary · context
Patients received either standard treatment based on SSC direction (as group control), or additional Ulinastatin (urinary trypsin inhibitor) 300 K units per day+thymosin alpha1 (Maipuxin) 1.6 mg per day for 7 days (as treatment group 1, adopted in the first trial), or double dosage of the above agen…
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1745922102
02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In adults with severe sepsis, double-dose ulinastatin plus thymosin alpha1 lowered 90-day mortality compared with standard treatment.
In plain wordsIn adults with severe sepsis, ulinastatin plus thymosin alpha1 at double dose was linked to fewer deaths at 90 days than standard treatment.
Peptide
Thymosin alpha-1
Outcome
Decrease90-day mortality, second trial
Study
n = 342
Comparator
Standard treatment
Outcome group
Mortality · Infection
Measurements
90-day mortality
52.1%
control
90-day mortality
37.14%
treatment group 2
Source sentences
Summary
In the second trial (342 cases), the mortality of treatment group 2 decreased from 38.32% to 25.14% (P=0.0088), compared with group control at 28 days, and from 52.10% to 37.14% (P=0.0054) on 90 days.
2 context sentences(design, population, supporting numbers)
Summary · context
Totally, 433 adult patients developing severe sepsis with Marshall score 5-20 were enrolled.
Summary · context
Patients received either standard treatment based on SSC direction (as group control), or additional Ulinastatin (urinary trypsin inhibitor) 300 K units per day+thymosin alpha1 (Maipuxin) 1.6 mg per day for 7 days (as treatment group 1, adopted in the first trial), or double dosage of the above agen…
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1745922103
03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In adults with severe sepsis, double-dose ulinastatin plus thymosin alpha1 lowered the APACHE II score at 28 days compared with standard treatment.
In plain wordsIn adults with severe sepsis, a regimen of ulinastatin plus thymosin alpha1 at double dose lowered the illness severity score compared with standard treatment.
Peptide
Thymosin alpha-1
Outcome
DecreaseAPACHE II score at 28 days, second trial
Study
n = 342
Comparator
Standard treatment
Outcome group
Intensive care and hospital outcomes · Infection
Measurements
APACHE II
14.32 score
control
APACHE II
12.7 score
treatment group 2
Source sentences
Summary
APACHEIIalso decreased from 14.32 to 12.70 (P=0.0384) and monocyte HLA-DR/CD14+ increased from 40.13% to 51.65% (P=0.0092) on 28 days in treatment group 2.
2 context sentences(design, population, supporting numbers)
Summary · context
Totally, 433 adult patients developing severe sepsis with Marshall score 5-20 were enrolled.
Summary · context
Patients received either standard treatment based on SSC direction (as group control), or additional Ulinastatin (urinary trypsin inhibitor) 300 K units per day+thymosin alpha1 (Maipuxin) 1.6 mg per day for 7 days (as treatment group 1, adopted in the first trial), or double dosage of the above agen…
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1745922104
04HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In adults with severe sepsis, double-dose ulinastatin plus thymosin alpha1 raised monocyte HLA-DR/CD14+ at 28 days compared with standard treatment.
In plain wordsIn adults with severe sepsis, a regimen of ulinastatin plus thymosin alpha1 at double dose raised a monocyte immune marker compared with standard treatment.
Peptide
Thymosin alpha-1
Outcome
IncreaseMonocyte HLA-DR/CD14+ at 28 days, second trial
Study
n = 342
Comparator
Standard treatment
Outcome group
Immune response · Immune and inflammation
Measurements
Monocyte HLA-DR/CD14+
40.13%
control
Monocyte HLA-DR/CD14+
51.65%
treatment group 2
Source sentences
Summary
APACHEIIalso decreased from 14.32 to 12.70 (P=0.0384) and monocyte HLA-DR/CD14+ increased from 40.13% to 51.65% (P=0.0092) on 28 days in treatment group 2.
2 context sentences(design, population, supporting numbers)
Summary · context
Totally, 433 adult patients developing severe sepsis with Marshall score 5-20 were enrolled.
Summary · context
Patients received either standard treatment based on SSC direction (as group control), or additional Ulinastatin (urinary trypsin inhibitor) 300 K units per day+thymosin alpha1 (Maipuxin) 1.6 mg per day for 7 days (as treatment group 1, adopted in the first trial), or double dosage of the above agen…
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1745922105
05HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In adults with severe sepsis, ulinastatin plus thymosin alpha1 at the first dose did not differ from standard treatment in outcome variables at 28 days.
In plain wordsIn adults with severe sepsis, a regimen of ulinastatin plus thymosin alpha1 at the first dose did not differ from standard treatment at 28 days.
Peptide
Thymosin alpha-1
Outcome
No significant changeOutcome variables at 28 days, first trial
Study
n = 91
Comparator
Standard treatment
Outcome group
Intensive care and hospital outcomes · Infection
Source sentences
Summary
In the first trial (91 cases), there was no significant difference in variables between treatment group 1 and control at 28 days.
2 context sentences(design, population, supporting numbers)
Summary · context
Totally, 433 adult patients developing severe sepsis with Marshall score 5-20 were enrolled.
Summary · context
Patients received either standard treatment based on SSC direction (as group control), or additional Ulinastatin (urinary trypsin inhibitor) 300 K units per day+thymosin alpha1 (Maipuxin) 1.6 mg per day for 7 days (as treatment group 1, adopted in the first trial), or double dosage of the above agen…
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1745922101
06HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome
In adults with severe sepsis, other variables did not differ significantly between the ulinastatin plus thymosin alpha1 group and control.
In plain wordsIn adults with severe sepsis, other measures did not differ between the ulinastatin plus thymosin alpha1 regimen and standard treatment.
Peptide
Thymosin alpha-1
Outcome
No significant changeOther variables, second trial
Study
n: not reported in source
Comparator
Standard treatment
Outcome group
Intensive care and hospital outcomes · Infection
Source sentences
Summary
Other variables had no significant differences between two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Totally, 433 adult patients developing severe sepsis with Marshall score 5-20 were enrolled.
Summary · context
Patients received either standard treatment based on SSC direction (as group control), or additional Ulinastatin (urinary trypsin inhibitor) 300 K units per day+thymosin alpha1 (Maipuxin) 1.6 mg per day for 7 days (as treatment group 1, adopted in the first trial), or double dosage of the above agen…
In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.
Report a problemFND-1745922106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 17:28 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.